BPC-157 vs GLOW Stack (GHK-Cu + TB-500 + BPC-157)

BPC-157

BPC-157 is a synthetic 15-residue peptide whose sequence was taken from a larger protein reported in human gastric juice. That parent protein, named body protection compound, is described mainly in the papers of the group that reported it, and the peptide is known almost entirely through its own studies. Most published work comes from that single research group and is in rodents, covering models of tendon, ligament, muscle and bone injury, lesions of the stomach and intestine, and some nervous-system models. Human data are very limited, consisting of a few small reports rather than controlled trials. Independent replication outside the originating group is limited.

GLOW Stack (GHK-Cu + TB-500 + BPC-157)

This product is a blend of three research peptides, GHK-Cu, TB-500 and BPC-157, supplied together in a single preparation. GHK-Cu is the copper(II) complex of the tripeptide glycyl-histidyl-lysine, first isolated from human plasma. TB-500 is the synthetic seven-residue fragment Ac-LKKTETQ, copied from the actin-binding region of thymosin β4. BPC-157 is a synthetic 15-residue peptide whose sequence was taken from a protein described in gastric juice. Each has its own literature, mostly in cell culture and animal models, but no published study has tested the three together, and there are no data on their stability or behaviour as a mixture.

How BPC-157 acts

No receptor for BPC-157 has been identified. Rodent and cell studies have reported changes in several signalling systems, most often the nitric oxide system, VEGF receptor 2 signalling in endothelial cells, and the FAK–paxillin pathway in cultured tendon fibroblasts. Other papers describe interactions with dopamine and serotonin systems in animal models. Several studies have also examined growth-factor and early-response gene expression in injured tissue. Because many of these findings come from a small number of laboratories, using different models, the mechanism is best regarded as unsettled rather than as a known pathway.

How GLOW Stack (GHK-Cu + TB-500 + BPC-157) acts

No mechanism has been described for the blend itself, so only the components can be discussed, each on its own evidence. GHK binds copper(II) with high affinity, and the complex has been examined in fibroblast cultures for changes in collagen and glycosaminoglycan synthesis. Thymosin β4 binds monomeric actin and regulates how much is available for filament assembly; TB-500 copies LKKTETQ, the short sequence at the centre of that binding region, and how far the fragment shares the binding is not well established. The mode of action of BPC-157 is unsettled, with rodent and cell studies examining nitric oxide signalling and VEGF receptor pathways. Whether the three interact with one another has not been investigated.

The records side by side

• Type: BPC-157, Pentadecapeptide; GLOW Stack (GHK-Cu + TB-500 + BPC-157), Three-peptide blend
• Length: BPC-157, 15 amino acids; GLOW Stack (GHK-Cu + TB-500 + BPC-157), not recorded
• Molecular weight: BPC-157, 1419.5 g/mol; GLOW Stack (GHK-Cu + TB-500 + BPC-157), not recorded
• Molecular formula: BPC-157, C62H98N16O22; GLOW Stack (GHK-Cu + TB-500 + BPC-157), not recorded

Reading a comparison

A comparison places two records side by side; it does not merge them. Each description above is drawn from that compound's own record, and the two were not necessarily characterised by the same methods, at the same time, or to the same level of detail. Before comparing any attribute, it is worth establishing that both records describe the substance you think they describe — names are not identifiers, and two entries sharing a name can differ in salt form, stereochemistry or the convention used to state a mass. Where a figure carries no method beside it, the comparison is between two reported numbers rather than between two measurements.